Cystic Fibrosis Therapeutics Market To Reach $13.9 Billion By 2025: Grand View Research, Inc.
The global cystic fibrosis therapeutics market is expected to
reach USD 13.9 billion by 2025, according to a new report by Grand View
Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research
& development activities undertaken by key players, and favorable
initiatives undertaken by nonprofit organizations are expected to boost the
market over the forecast period.
The rising prevalence of CF
indicates the rising demand for treatment alternatives, thereby uplifting the
market. The key players operating in this market in collaboration with
nonprofit organizations focus on the development of novel therapeutics for
treatment. Some of the drugs that are under clinical studies are VX-445 +
tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.
Favorable initiatives taken by
regional and national nonprofit organizations is one of the key factors
propelling growth. These initiatives ensure support to CF patients. These
organizations aid in research & development activities of these
therapeutics and help improve the quality of life of these patients. For
instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986
to provide a collaborative and educational forum to CF professionals to share
advances in R&D related to CF therapeutics.
U.S. cystic fibrosis therapeutics market, by drug class,
2014 - 2025 (USD Million)
Browse full research report on Cystic
Fibrosis Therapeutics Market
Analysis:
Further
key findings from the report suggest:
- The global CF
therapeutics market size was estimated at USD 3,560.5 million in 2016 and
is expected to grow at a CAGR of 16.7% from 2017 to 2025
- The CFTR
modulator segment emerged as the largest segment in 2016 and the same
segment is anticipated to witness fastest growth over the next 8 years
owing to the approval of CFTR modulator, Orkambi and the presence of
various investigational compounds under the pipeline.
- Oral route of
administration emerged as the largest segment with revenue of USD 2,266.4
million due to the ease of administration and convenience
- North America
accounted for the largest market share owing to the presence of Caucasian
descents in this region. Improved healthcare infrastructure,
reimbursements, and initiatives undertaken by the nonprofit organizations
is expected to propel the market over forecast period,
- The key
players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis
AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies),
Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta
Therapeutics Inc., Allergan, and AstraZeneca
Comments
Post a Comment